REG - ValiRx PLC - Grant of options <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

29/10/2014 14:20

RNS Number : 1088V
ValiRx PLC
23 October 2014
23 October 2014
ValiRx Plc
("ValiRx"or the "Company")
Grant of options
ValiRx Plc (AIM: VAL), the AIM-quoted life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that on 22 October 2014, it granted 149,000,000 options over ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to certain employees and directors of the Company, as set out in the table below.
Name of director
Number of shares held
% of issued share capital
Number of existing options
Number of new options granted
Total options now held
Options held as % of issued share capital
Satu Vainikka
23,113,714
0.79%
35,000,000
24,000,000
59,000,000
2.02%
George Morris
18,535,993
0.63%
28,750,000
22,000,000
50,750,000
1.74%
Gerry Desler
12,733,921
0.44%
28,400,000
22,000,000
50,400,000
1.73%
Kevin Alexander
8,034,843
0.28%
26,400,000
20,000,000
46,400,000
1.59%
Oliver de Giorgio-Miller
2,444,411
0.08%
23,000,000
20,000,000
43,000,000
1.47%
Seppo Makinen
1,273,387
0.04%
8,000,000
20,000,000
28,000,000
0.96%
Total Directors
66,136,269
2.26%
149,550,000
128,000,000
277,550,000
9.51%







Other employees
Nil
Nil
23,100,000
21,000,000
44,100,000
1.51%







Total
66,136,269
2.26%
172,650,000
149,000,000
321,650,000
11.02%
The new options were granted under the Company's stock option plan and have an exercise price of 0.36p pence. The new options are exercisable from 22 October 2014 until 21 October 2024.
Following the grant of the new options, the total number of Ordinary Shares under option held by directors, which could be issued, is 277,550,000 Ordinary Shares, representing approximately 9.51 per cent. of the current issued share capital of the Company.
In addition, a further 21,000,000 options have been granted to employees of the Company at an exercise price of 0.36 pence which are exercisable until 21 October 2024. 
The issued share capital of the Company comprises 2,921,043,420 ordinary shares of 0.1 pence each.
For more information, please contact:
ValiRx plc
Tel: +44 (0)20 3008 4416
Dr Satu Vainikka
www.ValiRx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0)20 7148 7900
Liam Murray / Avi Robinson



Daniel Stewart & Company Plc (Broker)
Tel: +44 (0)20 7776 6550
Martin Lampshire/ Mark Treharne

Peckwater PR
Tel: +44 (0)7879 458 364
Tarquin Edwards
tarquin.edwards@peckwaterpr.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSGCBDGGSDBGSX